Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study
Authors' conclusion
Lp(a) levels ≥30 mg/dL independently predicted adverse cardiovascular outcomes, regardless of baseline ASCVD status.
Study context
- Population
- Taiwanese individuals, Chang Gung Research Database (January 2004 to June 2019), without atherosclerotic cardiovascular disease (ASCVD) and with established ASCVDwithout ASCVD 49,363 · with established ASCVD 2,571
- Participants
- 51,934 individuals
- Exposure
- Lp ≥30 mg/dL vs <30 mg/dL
- Outcome
- MACE:
- Acute MI
- Ischemic stroke
- Revascularization
- Peripheral arterial interventions
- CV mortality
- Follow-up
- Mean 6.6 years
Methodological detailsmulti-institutional
- Multi-institutional
Main finding
As reported in the abstract
MACE
Each group vs Lp(a) <30 mg/dLAdjusted subdistribution hazard ratio (95% CI)
Lp(a) ≥30 mg/dLASCVD-free individuals
1.24(1.07–1.43)
Elevated Lp(a)ASCVD cohort
1.36(1.07–1.74)
Observational data: associations, not effects.
Further findings
Lp(a) concentration, study population
- Median Lp(a), mg/dL (IQR 4.6-18.5)
- 9.6
Restricted cubic spline analysis
- Progressive risk elevation beyond the 30 mg/dL threshold in both groups
Original publication
Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study. Eur J Prev Cardiol. Published 22 October 2025. doi:10.
Summarised from the published abstract; every number is checked against it